577 related articles for article (PubMed ID: 26559373)
1. Constitutive activation of STAT3 in breast cancer cells: A review.
Banerjee K; Resat H
Int J Cancer; 2016 Jun; 138(11):2570-8. PubMed ID: 26559373
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.
Alshaker H; Wang Q; Frampton AE; Krell J; Waxman J; Winkler M; Stebbing J; Cooper C; Yagüe E; Pchejetski D
Breast Cancer Res Treat; 2015 Jan; 149(1):59-67. PubMed ID: 25481644
[TBL] [Abstract][Full Text] [Related]
3. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.
Siersbæk R; Scabia V; Nagarajan S; Chernukhin I; Papachristou EK; Broome R; Johnston SJ; Joosten SEP; Green AR; Kumar S; Jones J; Omarjee S; Alvarez-Fernandez R; Glont S; Aitken SJ; Kishore K; Cheeseman D; Rakha EA; D'Santos C; Zwart W; Russell A; Brisken C; Carroll JS
Cancer Cell; 2020 Sep; 38(3):412-423.e9. PubMed ID: 32679107
[TBL] [Abstract][Full Text] [Related]
4. Targeting the IL-6/JAK/STAT3 signalling axis in cancer.
Johnson DE; O'Keefe RA; Grandis JR
Nat Rev Clin Oncol; 2018 Apr; 15(4):234-248. PubMed ID: 29405201
[TBL] [Abstract][Full Text] [Related]
5. Necdin, a negative growth regulator, is a novel STAT3 target gene down-regulated in human cancer.
Haviland R; Eschrich S; Bloom G; Ma Y; Minton S; Jove R; Cress WD
PLoS One; 2011; 6(10):e24923. PubMed ID: 22046235
[TBL] [Abstract][Full Text] [Related]
6. Terpenoid-Mediated Targeting of STAT3 Signaling in Cancer: An Overview of Preclinical Studies.
Khan F; Pandey P; Verma M; Upadhyay TK
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397437
[TBL] [Abstract][Full Text] [Related]
7. Silencing of p68 and STAT3 synergistically diminishes cancer progression.
Hashemi V; Ahmadi A; Malakotikhah F; Chaleshtari MG; Baghi Moornani M; Masjedi A; Sojoodi M; Atyabi F; Nikkhoo A; Rostami N; Baradaran B; Azizi G; Yousefi B; Ghalamfarsa G; Jadidi-Niaragh F
Life Sci; 2020 May; 249():117499. PubMed ID: 32142763
[TBL] [Abstract][Full Text] [Related]
8. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
Adesoye T; Tripathy D; Hunt KK; Keyomarsi K
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339245
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
Hu Y; Dong Z; Liu K
J Exp Clin Cancer Res; 2024 Jan; 43(1):23. PubMed ID: 38245798
[TBL] [Abstract][Full Text] [Related]
10. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract][Full Text] [Related]
11. The pleiotropic role of transcription factor STAT3 in oncogenesis and its targeting through natural products for cancer prevention and therapy.
Garg M; Shanmugam MK; Bhardwaj V; Goel A; Gupta R; Sharma A; Baligar P; Kumar AP; Goh BC; Wang L; Sethi G
Med Res Rev; 2020 Dec; ():. PubMed ID: 33289118
[TBL] [Abstract][Full Text] [Related]
12. Contribution of Signal Transducer and Activator of Transcription 3 (STAT3) to Bone Development and Repair.
Sobah ML; Liongue C; Ward AC
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203559
[TBL] [Abstract][Full Text] [Related]
13. Major Functional Transcriptome of an Inferred Center Regulator of an ER(-) Breast Cancer Model System.
Liu LY; Chang LY; Kuo WH; Hwa HL; Lin YS; Huang SF; Chen CN; Chang KJ; Hsieh FJ
Cancer Inform; 2012; 11():87-111. PubMed ID: 22553414
[TBL] [Abstract][Full Text] [Related]
14. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
[TBL] [Abstract][Full Text] [Related]
15. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
[TBL] [Abstract][Full Text] [Related]
16. STAT3 signaling in immunity.
Hillmer EJ; Zhang H; Li HS; Watowich SS
Cytokine Growth Factor Rev; 2016 Oct; 31():1-15. PubMed ID: 27185365
[TBL] [Abstract][Full Text] [Related]
17. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
18. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism.
Zhao C; Li H; Lin HJ; Yang S; Lin J; Liang G
Trends Pharmacol Sci; 2016 Jan; 37(1):47-61. PubMed ID: 26576830
[TBL] [Abstract][Full Text] [Related]
19. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment.
Kim BH; Yi EH; Ye SK
Arch Pharm Res; 2016 Aug; 39(8):1085-99. PubMed ID: 27515050
[TBL] [Abstract][Full Text] [Related]
20. The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations.
Geiger JL; Grandis JR; Bauman JE
Oral Oncol; 2016 May; 56():84-92. PubMed ID: 26733183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
